Advanced search
Publication Cover
Leukemia & Lymphoma Volume 60, 2019 - Issue 9
Submit an article Journal homepage
347
Views
6
CrossRef citations to date
0
Altmetric
Letters to the Editor

Enhancing the feasibility of outpatient daratumumab administration via a split-dosing strategy with initial doses

Justin R. ArnallDepartment of Pharmacy, Atrium Health, Levine Cancer Institute, Charlotte, NC, USA; View further author information
,
Donald C. MooreDepartment of Pharmacy, Atrium Health, Levine Cancer Institute, Charlotte, NC, USA; Correspondence[email protected]
View further author information
,
Hailey L. HillDepartment of Pharmacy, Atrium Health, Carolinas Medical Center, Charlotte, NC, USA; View further author information
,
Sarah GriffinInova Fairfax Hospital, Falls Church, VA, USA; View further author information
,
Maxine K. MuellerDepartment of Pharmacy, Atrium Health, Levine Cancer Institute, Charlotte, NC, USA; View further author information
,
Lesli A. LaveryDepartment of Pharmacy, Atrium Health, Levine Cancer Institute, Charlotte, NC, USA; View further author information
,
Peter M. VoorheesDepartment of Hematologic Oncology and Blood Disorders, Atrium Health, Levine Cancer Institute, Charlotte, NC, USAView further author information
&
Saad Z. UsmaniDepartment of Hematologic Oncology and Blood Disorders, Atrium Health, Levine Cancer Institute, Charlotte, NC, USAView further author information
 show all
Pages 2295-2298 | Received 18 Oct 2018, Accepted 22 Jan 2019, Published online: 08 Mar 2019
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days
Click to increase image sizeClick to decrease image sizeFree first page

Potential conflict of interest

Disclosure forms provided by the authors are available with the full text of this article online at http:\\doi:10.1080/10428194.2019.1576871

Additional information

Funding

Dr. Voorhees has received consulting fees from Adaptive, Amgen, BMS, Celgene, Janssen, Novartis, Oncopeptides, Takeda, and TeneoBio and speakers fees for Amgen, Celgene, and Janssen. Dr. Usmani has received consulting fees from Amgen, BMS, Celgene, Janssen, Merck, SkylineDx, and Takeda and speakers fees from Amgen, Celgene, Janssen, Sanofi, and Takeda.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.